American Society of Clinical OncologyRevised Neuroblastoma Risk Classification System: A Report from the Children’s Oncology Group
It was time for a change in neuroblastoma treatment planning, and this Original Report from the Journal of Clinical Oncology validates a revised classifier using the International Neuroblastoma Risk Group Staging System (INRGSS) while incorporating segmental chromosome aberrations (SCA) as an additional genomic biomarker.